AU2019378076B2 - Immunogenic Arginase 2 polypeptides - Google Patents

Immunogenic Arginase 2 polypeptides

Info

Publication number
AU2019378076B2
AU2019378076B2 AU2019378076A AU2019378076A AU2019378076B2 AU 2019378076 B2 AU2019378076 B2 AU 2019378076B2 AU 2019378076 A AU2019378076 A AU 2019378076A AU 2019378076 A AU2019378076 A AU 2019378076A AU 2019378076 B2 AU2019378076 B2 AU 2019378076B2
Authority
AU
Australia
Prior art keywords
arg2
cells
cancer
polypeptide
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019378076A
Other languages
English (en)
Other versions
AU2019378076A1 (en
Inventor
Mads Hald Andersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IO Biotech ApS
Original Assignee
IO Biotech ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IO Biotech ApS filed Critical IO Biotech ApS
Publication of AU2019378076A1 publication Critical patent/AU2019378076A1/en
Application granted granted Critical
Publication of AU2019378076B2 publication Critical patent/AU2019378076B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03001—Arginase (3.5.3.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2019378076A 2018-11-14 2019-11-14 Immunogenic Arginase 2 polypeptides Active AU2019378076B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1818576.9 2018-11-14
GBGB1818576.9A GB201818576D0 (en) 2018-11-14 2018-11-14 Arginase 2 polypeptides
PCT/EP2019/081369 WO2020099582A1 (en) 2018-11-14 2019-11-14 Immunogenic arginase 2 polypeptides

Publications (2)

Publication Number Publication Date
AU2019378076A1 AU2019378076A1 (en) 2021-05-27
AU2019378076B2 true AU2019378076B2 (en) 2025-08-07

Family

ID=64739444

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019378076A Active AU2019378076B2 (en) 2018-11-14 2019-11-14 Immunogenic Arginase 2 polypeptides

Country Status (11)

Country Link
US (2) US12234288B2 (https=)
EP (1) EP3880225A1 (https=)
JP (1) JP7611137B2 (https=)
KR (1) KR20210093287A (https=)
CN (1) CN113164545B (https=)
AU (1) AU2019378076B2 (https=)
CA (1) CA3118794A1 (https=)
GB (1) GB201818576D0 (https=)
IL (1) IL283133B1 (https=)
SG (1) SG11202104881VA (https=)
WO (1) WO2020099582A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201818576D0 (en) * 2018-11-14 2018-12-26 Io Biotech Aps Arginase 2 polypeptides
GB201912030D0 (en) * 2019-08-21 2019-10-02 Cancer Research Tech Ltd Binding molecules
WO2023161350A1 (en) 2022-02-24 2023-08-31 Io Biotech Aps Nucleotide delivery of cancer therapy
JP2025508840A (ja) 2022-02-24 2025-04-10 アイオー バイオテック エーピーエス アルギナーゼ２ワクチン

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1033401A2 (en) * 1999-02-26 2000-09-06 Genset Expressed sequence tags and encoded human proteins
US20020119554A1 (en) * 1996-03-14 2002-08-29 Vockley Joseph G. Arginase II
US20070014801A1 (en) * 2001-01-24 2007-01-18 Gish Kurt C Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
AU2002215345A1 (en) * 2000-10-13 2002-04-22 Eos Biotechnology, Inc. Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
PT3778885T (pt) * 2008-10-31 2023-05-31 Aerase Inc Composições de arginases humanas modificadas e métodos para o tratamento do cancro
CA2988388C (en) * 2015-04-23 2022-11-22 Nantomics, Llc Cancer neoepitopes
DK3423087T3 (da) * 2016-03-04 2023-12-18 Io Biotech Aps Kombinationsterapi mod cancer
GB2568000A (en) * 2016-08-08 2019-05-01 Aerase Inc Compositions and methods for treating cancer with arginine depletion and immuno oncology agents
JP7211938B2 (ja) * 2016-10-07 2023-01-24 アイオー バイオテック エーピーエス 免疫原性アルギナーゼペプチド
GB201815549D0 (en) 2018-09-24 2018-11-07 Io Biotech Aps Arginase1 polypeptides
GB201818576D0 (en) * 2018-11-14 2018-12-26 Io Biotech Aps Arginase 2 polypeptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119554A1 (en) * 1996-03-14 2002-08-29 Vockley Joseph G. Arginase II
EP1033401A2 (en) * 1999-02-26 2000-09-06 Genset Expressed sequence tags and encoded human proteins
US20070014801A1 (en) * 2001-01-24 2007-01-18 Gish Kurt C Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer

Also Published As

Publication number Publication date
CN113164545A (zh) 2021-07-23
IL283133A (en) 2021-06-30
GB201818576D0 (en) 2018-12-26
JP7611137B2 (ja) 2025-01-09
US12234288B2 (en) 2025-02-25
CN113164545B (zh) 2026-04-10
AU2019378076A1 (en) 2021-05-27
CA3118794A1 (en) 2020-05-22
SG11202104881VA (en) 2021-06-29
KR20210093287A (ko) 2021-07-27
EP3880225A1 (en) 2021-09-22
JP2022507373A (ja) 2022-01-18
WO2020099582A1 (en) 2020-05-22
IL283133B1 (en) 2026-03-01
US20210403566A1 (en) 2021-12-30
US20250388674A1 (en) 2025-12-25

Similar Documents

Publication Publication Date Title
US20250388674A1 (en) Immunogenic arginase 2 polypeptides
AU2020287902B2 (en) TGF-beta vaccine
US20250205318A1 (en) Arginase1 polypeptides
US20200299401A1 (en) Enhancement of antibody-dependent cell-mediated cytotoxicity (adcc)
US20250161422A1 (en) Arginase 2 vaccine
IL320588A (en) TGF-beta-1 vaccine

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)